| Revenue growth | Flat YoY at consolidated level; high subsidiary growth offset standalone decline. |
|---|---|
| Margins | EBITDA margins expanded significantly; Innoxel turned EBITDA positive in Q4. |
| Order book | ₹171cr for BPL standalone providing FY27 visibility. |
| Demand visibility | Strong; order book at ₹171cr for standalone business. |
| Management confidence | High confidence in FY27 guidance after finishing investment phase. |
Growth
FY26 Consolidated Revenue: ₹345.4cr (+1.6% YoY); EBITDA: ₹15.8cr (+485% YoY). Innoxel grew 174% to ₹72.4cr.
Outlook
FY27 Guidance: Standalone growth 10-15%; Innoxel 35-45%; Varenyam 20-25%. Peak revenue targets ₹400-500cr by 2030.
Risks
Soft standalone exports due to deferred tenders; geopolitical disturbances causing 3-month project delays; near-term disruption from audits.
Earnings Call filed with BSE, BSE: 541096. Summary written with AI assistance from the document.
Bharat Parenterals Ltd: key numbers
- Share price
- ₹1,842.35
- Market cap
- ₹1,270 Cr
- Revenue (annual)
- ₹345.4 Cr
- Net profit (annual)
- ₹-8.19 Cr
- P/E (TTM)
- -82.4×Sector 47.4×
- Promoter holding
- 67.20%+0.03% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bharat Parenterals Ltd
All →Bharat Parenterals Board Meeting Date
Bharat Parenterals intimated that its Board will meet on 29 September 2026 to consider a preferential equity issue. The agenda item is proposed, not yet approved, with no amount disclosed.
Bharat Parenterals Management Change
Bharat Parenterals Limited has re-appointed Mr. Hemang Jayendrabhai Shah as Executive Director for a 5-year term effective July 2, 2026.
Bharat Parenterals Annual General Meeting
Bharat Parenterals Limited held its 33rd Annual General Meeting on September 19, 2026. The proceedings covered the adoption of financial statements and various resolutions.
Bharat Parenterals Dividend
Bharat Parenterals Limited has fixed September 12, 2026, as the record date to determine shareholder eligibility for the dividend for FY 2025-26.
Bharat Parenterals Annual Report
Bharat Parenterals Limited has submitted its Annual Report for the financial year 2025-26. The report includes the notice for the 33rd Annual General Meeting.
Bharat Parenterals Annual General Meeting
Bharat Parenterals Limited has scheduled its 33rd Annual General Meeting on September 19, 2026, to discuss financial results, dividend declaration, and director reappointments.